PETRARCA, ANTONIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.406
EU - Europa 659
AS - Asia 178
Continente sconosciuto - Info sul continente non disponibili 2
AF - Africa 1
Totale 2.246
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.403
SE - Svezia 144
PL - Polonia 134
IE - Irlanda 123
CN - Cina 69
HK - Hong Kong 67
IT - Italia 54
DE - Germania 48
RU - Federazione Russa 46
UA - Ucraina 37
FI - Finlandia 30
GB - Regno Unito 26
SG - Singapore 20
TR - Turchia 13
BE - Belgio 10
JO - Giordania 7
CZ - Repubblica Ceca 4
CA - Canada 2
CH - Svizzera 2
EU - Europa 2
VN - Vietnam 2
FR - Francia 1
MX - Messico 1
SC - Seychelles 1
Totale 2.246
Salva come PNG Salva come JPEG
Città #
Fairfield 193
Chandler 164
Warsaw 134
Dublin 123
Ashburn 122
Wilmington 88
Seattle 87
Cambridge 85
Ann Arbor 83
Woodbridge 79
Jacksonville 64
Houston 58
Beijing 43
Hong Kong 42
Boardman 31
Princeton 30
Buffalo 28
Boston 23
Bremen 23
Altamura 22
Lawrence 20
San Diego 15
Shanghai 14
Izmir 12
Falls Church 11
Medford 11
Singapore 11
Brussels 10
Andover 6
Norwalk 5
Brno 4
New York 4
Old Bridge 4
Washington 4
Ferriere 3
Montalbano Jonico 3
Bern 2
Dong Ket 2
Florence 2
Hillsboro 2
Kent 2
London 2
Padova 2
Toronto 2
West Jordan 2
Auburn Hills 1
Brescia 1
Brooklyn 1
Chieti 1
Frankfurt Am Main 1
Genoa 1
Grevenbroich 1
Hangzhou 1
Laurel 1
Leawood 1
Los Angeles 1
Mérida 1
Nanjing 1
Phoenix 1
Portland 1
Redmond 1
Salerno 1
San Mateo 1
Santa Clara 1
St Petersburg 1
Tappahannock 1
Terni 1
Verona 1
Totale 1.700
Salva come PNG Salva come JPEG
Nome #
Assessment of liver stiffness in patients with HCV and mixed cryoglobulinemia undergoing rituximab treatment. 196
Acute viral hepatitis increases liver stiffness values measured by transient elastography 120
Modifications of plasma platelet-activating factor (PAF)- acetylhydrolase/PAF system activity in patients with chronic hepatitis C virus infection 113
Association Between Persistent Lymphatic Infection By Hepatitis C Virus After Antiviral Treatment And Mixed Cryoglobulinemia 112
A phase II, single-arm multicenter study of low-dose rituximab for refractory mixed cryoglobulinemia secondary to hepatitis C virus infection 112
Host genetic determinants in HCV-related mixed cryoglobulinemia 111
Reliability of transient elastography for the diagnosis of advanced fibrosis in chronic hepatitis C 102
Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease 99
Host genetic determinants in HCV-related mixed cryoglobulinemia 97
Can BAFF promoter polymorphism be a predisposing condition for HCV-related mixed cryoglobulinemia? 92
Effect of chronic hepatitis C virus infection on inflammatory lipid mediators 92
Transient elastography (TE) is more effective for the identification of HCV patients with advanced (F3-F4) rather than significant (F2-F4) liver fibrosis 82
Improvement in liver cirrhosis after treatment of HCV-related mixed cryoglobulinemia with rituximab 82
HCV-related mixed cryoglobulinemia and BAFF promoter polymorphism 81
Transient elastography (TE) is more effective for the identification of HCV patients with severe (> F3) rather than significant (> F2) liver fibrosis 78
Analysis of HCV persistence in patients with sustained virological response 76
Host genetic determinants in HCV-related mixed cryoglobulinemia 69
VALUE OF IL28B GENOTYPING IN PATIENTS WITH HCV-RELATED MIXED CRYOGLOBULINEMIA: RESULTS OF A LARGE, PROSPECTIVE STUDY 65
Behaviour of sustained responders to anti-HCV treatment: may HCV infection be eradicated? 55
Genetic determinants in Hepatitis C Virus-associated mixed cryoglobulinemia: role of polymorphic variants of BAFF promoter and Fc-gamma receptors 44
Il polimorfismo dell'interleuchina 28B come predittore di risposta in pazienti con crioglobulinemia mista HCV-correlata 43
IL28B polymorphism as predictor of response to anti-HCV terapy in HCV-related mixed cryoglobulinemia syndrome 41
Efficacy of rituximab in severe and mild abdominal vasculitis in the course of mixed cryoglobulinemia 40
Mixed cryoglobulinemia syndrome is a negative prognostic factor in the standard of care (Peg-IFN+ribavirin) anti-HCV therapy 39
Effect of rituximab on advanced liver disease in patients with HCV-related mixed cryoglobulinemia. 39
Can depletion of B-cells by anti-CD20 monoclonal antibody in HCV plus mixed cryoglobulinemia (MC) improve liver cirrhosis? 38
Effects of depletion of B cell by anti-CD20 monoclonal antibody in HCV+ mixed cryoglobulinemia (MC) and liver cirrhosis 37
Long-term outcome of HCV-related mixed cryoglobulinemia in patients achieving sustained viral sustained viral response (SVR) after antiviral therapy 35
L'epatite B: un problema antico di rinnovata attualità 31
Utilizzo del Rituximab (Anticorpo Monoclonale anti-CD20) nel Trattamento dei Pazienti con Sindrome Crioglobulinemica HCV-correlata e Malattia Epatica Avanzata 28
Totale 2.249
Salva come PNG Salva come JPEG
Categoria #
all - tutte 6.678
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.678
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020440 0 34 10 42 45 53 46 56 53 50 45 6
2020/2021262 29 15 27 22 6 34 9 22 24 33 24 17
2021/2022237 7 31 4 10 13 9 11 15 11 5 51 70
2022/2023621 53 69 35 68 64 115 75 41 82 4 13 2
2023/2024192 14 23 32 15 9 31 5 53 2 2 2 4
2024/202582 64 18 0 0 0 0 0 0 0 0 0 0
Totale 2.249